Interpretation of the Chinese expert consensus on treatment of non-infectious uveitis with anti-tumor necrosis factor-alpha monoclonal antibody
10.3760/cma.j.cn511434-20240104-00005
- VernacularTitle:《抗肿瘤坏死因子-α单克隆抗体治疗非感染性葡萄膜炎中国专家共识》解读
- Author:
Xizi WANG
1
;
Wenjie ZHENG
;
Xiaomin ZHANG
Author Information
1. 天津医科大学眼科医院、眼视光学院、眼科研究所 国家眼耳鼻喉疾病临床医学研究中心天津市分中心 天津市视网膜功能与疾病重点实验室，天津 300384
- Keywords:
Anti-tumor necrosis factor-α monoclonal antibody;
Non-infectious uveitis;
Expert consensus;
Interpretation
- From:
Chinese Journal of Ocular Fundus Diseases
2024;40(1):20-26
- CountryChina
- Language:Chinese
-
Abstract:
As a new treatment option after conventional corticosteroids and immunomodulatory drugs, biologics have been widely used in the clinical management of non-infectious uveitis in many countries due to their approved efficacy and safety. Anti-tumor necrosis factor-alpha monoclonal antibody is the most commonly used one. However, the guidance on its standardized application is lacking. The Ocular Immunology Group of Immunology and Rheumatology Academy in Cross-Straits Medicine Exchange Association compiled the Chinese expert consensus on treatment of non-infectious uveitis with anti-tumor necrosis factor-alpha monoclonal antibody. This evidence-based consensus is made according to the principle of consensus building and combines the clinical experience of the experts. Twelve recommendations are formatted on the application of Adalimumab and Infliximab. The interpretation of this consensus point will help improve the normative and effective application of anti-tumor necrosis factor-alpha monoclonal antibody in ophthalmologists, rheumatologists and immunologists.
